UA102236C2 - Похідні еритропоетин-міметичного пептиду та їх фармацевтичні солі, їх одержання і застосування - Google Patents

Похідні еритропоетин-міметичного пептиду та їх фармацевтичні солі, їх одержання і застосування

Info

Publication number
UA102236C2
UA102236C2 UAA201007321A UAA201007321A UA102236C2 UA 102236 C2 UA102236 C2 UA 102236C2 UA A201007321 A UAA201007321 A UA A201007321A UA A201007321 A UAA201007321 A UA A201007321A UA 102236 C2 UA102236 C2 UA 102236C2
Authority
UA
Ukraine
Prior art keywords
pharmaceutical salt
mimetic peptide
peptide derivatives
preparation
erythropoietin mimetic
Prior art date
Application number
UAA201007321A
Other languages
English (en)
Russian (ru)
Inventor
Айфенг Лю
Чанган Сун
Тао Джянг
Вентао Ву
Ялі Ванг
Original Assignee
Джянгсу Хансох Фармасьютікал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джянгсу Хансох Фармасьютікал Ко., Лтд. filed Critical Джянгсу Хансох Фармасьютікал Ко., Лтд.
Publication of UA102236C2 publication Critical patent/UA102236C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Винахід належить до похідних ЕРО міметичного пептиду формули (І) R1-R2-(CH2)nl-R3-(CH2)n2-R4-R5, (I) де R1, R2, R3, R4, R5, n1, n2 є такими, як зазначено в описі винаходу, до їх фармацевтичних солей, одержання таких. Композиція включає похідні ЕРО міметичного пептиду формули (І) і їх фармацевтично прийнятні солі. Винахід також належить до застосування похідних і їх фармацевтично прийнятних солей, до застосування композиції для лікування захворювань, що характеризуються дефіцитом ЕРО, недостатньою або дефектною популяцією еритроцитів.
UAA201007321A 2007-12-12 2008-11-24 Похідні еритропоетин-міметичного пептиду та їх фармацевтичні солі, їх одержання і застосування UA102236C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNA2007101987519A CN101456911A (zh) 2007-12-12 2007-12-12 促红细胞生成素模拟肽衍生物及其可药用盐和其制备方法与用途
PCT/CN2008/001909 WO2009079910A1 (en) 2007-12-12 2008-11-24 An erythropoietin mimetic peptide derivatives and its pharmaceutical salt, the preparation and uses thereof

Publications (1)

Publication Number Publication Date
UA102236C2 true UA102236C2 (uk) 2013-06-25

Family

ID=40768057

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201007321A UA102236C2 (uk) 2007-12-12 2008-11-24 Похідні еритропоетин-міметичного пептиду та їх фармацевтичні солі, їх одержання і застосування

Country Status (16)

Country Link
US (1) US8642545B2 (uk)
EP (1) EP2233504B1 (uk)
JP (1) JP5448099B2 (uk)
KR (1) KR101646929B1 (uk)
CN (2) CN101456911A (uk)
AU (1) AU2008341661B9 (uk)
BR (1) BRPI0820749B8 (uk)
CA (1) CA2708819C (uk)
ES (1) ES2541139T3 (uk)
HK (1) HK1136837A1 (uk)
MX (1) MX2010006436A (uk)
RU (1) RU2493168C2 (uk)
TW (1) TWI419706B (uk)
UA (1) UA102236C2 (uk)
WO (1) WO2009079910A1 (uk)
ZA (1) ZA201003998B (uk)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158493A2 (en) * 2011-05-19 2012-11-22 Geysen Hendrik M Compounds that bind to the erythropoietin receptor
WO2013158871A1 (en) 2012-04-20 2013-10-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of erythropoietin and derivatives for treating hypertension
CN103450348B (zh) * 2012-05-29 2016-03-30 中国人民解放军军事医学科学院毒物药物研究所 一种促红细胞生成素模拟肽、其制备方法和用途
CN103536900B (zh) * 2012-07-16 2017-06-16 江苏豪森药业集团有限公司 含有促红细胞生成素模拟肽的药物组合物
CN103570834A (zh) * 2012-07-19 2014-02-12 江苏豪森药业股份有限公司 甲氧基聚乙二醇修饰的促红细胞生成素模拟肽衍生物
CN112245586A (zh) 2013-03-15 2021-01-22 小利兰·斯坦福大学托管委员会 用于实现治疗有效剂量的抗cd47剂的方法
CN104231039A (zh) * 2013-06-08 2014-12-24 江苏豪森药业股份有限公司 用于合成促红细胞生成素模拟肽衍生物的功能小分子及其制备方法
CN105085653B (zh) * 2015-08-26 2019-01-08 天津药物研究院有限公司 一种促红细胞生成素模拟肽及其制备方法和应用
CN106608912B (zh) * 2015-10-22 2019-09-20 天津药物研究院有限公司 一种脂肪二羧酸偶联的epo模拟肽衍生物及其制备方法和应用
CN106608913B (zh) * 2015-10-22 2020-05-05 天津药物研究院有限公司 一种1，2，3-丙三酸偶联的epo拟肽衍生物及其制备方法和应用
CN105367629B (zh) * 2015-11-09 2019-01-08 天津药物研究院有限公司 一种促红细胞生成素模拟肽以及其制备方法和用途
CN106928338A (zh) * 2015-12-31 2017-07-07 杭州阿德莱诺泰制药技术有限公司 促红细胞生成素肽及衍生物和聚合物、制备方法和应用
WO2018011302A1 (en) 2016-07-12 2018-01-18 Hexal Ag Glycoprotein with reduced acetylation rate of sialic acid residues
CN108236717A (zh) * 2016-12-27 2018-07-03 江苏豪森药业集团有限公司 聚乙二醇连接臂与所修饰多肽药物的偶合物
JP7445978B2 (ja) * 2018-09-14 2024-03-08 エポメッド株式会社 抗エリスロポエチン受容体ペプチド
KR102073886B1 (ko) 2019-05-02 2020-02-05 주식회사 미래와바다 잘피이식용 다공질 패널
CN114601916B (zh) * 2022-04-12 2024-04-16 江苏豪森药业集团有限公司 一种培化西海马肽注射制剂及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008822A1 (en) 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
KR100459984B1 (ko) * 1995-06-07 2005-06-20 아피맥스 테크놀로지스, 엔.브이. 에리트로포이에틴수용체(epo-r)에결합하는화합물및펩티드
CA2262994A1 (en) * 1996-08-02 1998-02-12 Ortho-Mcneil Pharmaceutical, Inc. Polypeptides having a single covalently bound n-terminal water-soluble polymer
RU2281116C2 (ru) * 2000-05-15 2006-08-10 Ф.Хоффманн-Ля Рош Аг Новая фармацевтическая композиция
CN1169827C (zh) * 2001-08-07 2004-10-06 沈阳三生制药股份有限公司 一种增强多肽在体内稳定性药物的生产方法及其应用
US7084245B2 (en) * 2003-05-12 2006-08-01 Affymax, Inc. Peptides that bind to the erythropoietin receptor
DK1625156T3 (da) * 2003-05-12 2013-01-07 Affymax Inc Peptider, der bindes til erythropoietinreceptoren
CN1820024B (zh) * 2003-05-12 2011-06-22 阿费麦克斯公司 新的聚(乙二醇)修饰的化合物及其用途
CN100362019C (zh) * 2004-03-02 2008-01-16 成都生物制品研究所 聚乙二醇修饰后具有体内生理活性的重组促红细胞生成素
AU2005310189A1 (en) * 2004-11-11 2006-06-08 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor

Also Published As

Publication number Publication date
ES2541139T3 (es) 2015-07-16
BRPI0820749A2 (pt) 2015-06-16
JP2011506350A (ja) 2011-03-03
BRPI0820749B1 (pt) 2020-11-24
MX2010006436A (es) 2010-10-06
CN101675080A (zh) 2010-03-17
AU2008341661A1 (en) 2009-07-02
AU2008341661B2 (en) 2013-08-08
TWI419706B (zh) 2013-12-21
KR20110025731A (ko) 2011-03-11
BRPI0820749B8 (pt) 2021-05-25
KR101646929B1 (ko) 2016-08-09
JP5448099B2 (ja) 2014-03-19
EP2233504A4 (en) 2011-03-09
TW201002352A (en) 2010-01-16
CA2708819A1 (en) 2009-07-02
US20100323949A1 (en) 2010-12-23
HK1136837A1 (en) 2010-07-09
CN101456911A (zh) 2009-06-17
CN101675080B (zh) 2012-07-11
WO2009079910A1 (en) 2009-07-02
CA2708819C (en) 2018-05-15
AU2008341661B9 (en) 2013-08-15
US8642545B2 (en) 2014-02-04
RU2493168C2 (ru) 2013-09-20
ZA201003998B (en) 2011-10-26
EP2233504A1 (en) 2010-09-29
WO2009079910A8 (zh) 2009-11-19
EP2233504B1 (en) 2015-04-01
RU2010123466A (ru) 2012-01-20

Similar Documents

Publication Publication Date Title
UA102236C2 (uk) Похідні еритропоетин-міметичного пептиду та їх фармацевтичні солі, їх одержання і застосування
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
EA200970149A1 (ru) Производные n-(аминогетероарил)-1h-индол-2-карбоксамидов, их получение и их применение в терапии
MY143565A (en) Novel fluorocglycoside derivatives of pyrazoles: medicaments containing these compounds, and the use thereof
EA200870116A1 (ru) Бициклические гетероарильные соединения
DE502006006107D1 (de) Amid substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
TN2013000051A1 (en) 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin -4-one derivatives and their use as pde9a inhibitors
UY30472A1 (es) Nuevos derivados de pirimidina, procesos para su preparacion composiciones farmacéuticas conteniédolos, procesos para su preparacion y aplicaciones.
TW200606162A (en) Pyrazolopyridine derivatives
EA201190296A1 (ru) Дисахариновая, дифумарово-кислая, ди-1-гидрокси-2-нафтойно-кислая и монобензойно-кислая соли 4-(диметиламино)бутил-2-(4-((2-амино-4-метил-6-(пентиламино)пиримидин-5-ил)метил)фенил)ацетата
CY1116885T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου
UY29857A1 (es) Derivados de la 4-amino-quinazolina, su preparación y su aplicación en terapéutica.
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
EA200802214A1 (ru) 2,4-диаминопиримидины в качестве ингибиторов киназ, участвующих в регуляции клеточного цикла
EA201100255A1 (ru) 5-алкинилпиримидины
UY29041A1 (es) Derivados de amino-piperidina, su preparacion y su utilización en terapeutica
UY29859A1 (es) Derivados de 1-amino-isiquinolina,su preparación y su aplicación terapéutica
MX2012007896A (es) Derivados de piridino-piridinonas arilsulfonamidas, su preparacion y su uso en terapeutica.
DK1869038T3 (da) Substituerede 5,6,7,8-tetrahydro-imidazol[1,2-a]pyridin-2-ylamin-forbindelser og deres anvendelse til fremstilling af lægemidler
EA201190236A1 (ru) Новые производные стероидных соединений [3,2-c]пиразолов с глюкокортикоидной активностью
ATE531703T1 (de) Benzochromenderivate
NO20084177L (no) Substituerte Imidazo[2,1-B]thiazolforbindelser og deres anvendelse for produksjon av legemidler
ATE512968T1 (de) 1,2,3,4-tetrahydropyrrolo(1,2-a)pyrazin-6- carboxamid und 2,3,4,5-tetrahydropyrrolo(1,2-a)- diazepin-7-carboxamid- derivate, ihre herstellung und therapeutische verwendung
UY29046A1 (es) Derivados de n-(1h-indolil)-1h-indol-2-carboxamidas, su preparación y su uso en terapia